Investor Presentation Q1 2023

8 Investor presentation First three months of 2023 Novo NordiskⓇ GLP-1 class expansion accelerates in the US in the first quarter of 2023 with volume growth across our portfolio US GLP-1 weekly NBRx prescriptions Weekly NBRX scripts ('000s) 80 60 60 40 20 0 Apr 2021 Ozempic Rybelsus® US GLP-1 TRX market share TRX share Total GLP-1 scripts (millions) Class growth ~60% 60% 6 52.9% 5 40.9% 40% 4 29.8% 3 20% 16.3% 2 7.2% 1 4.7% 0% 0 Apr 2023 Apr 2021 Apr 2023 VictozaⓇ NN GLP-1 - dulaglutide tirzepatide Total monthly GLP-1 scripts NBRX: New-to-brand prescriptions; TRx: Total prescriptions; NN: Novo Nordisk; Scripts: Prescriptions; US: United States Note: Class growth calculated as Q1 2023 vs Q1 2022 Source: IQVIA Xponent, NBRx data from week ending 14 Apr 2023. TRX data from week ending 14 Apr 2023. Each data points represents a rolling four-week average

View entire presentation